AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating

Analyst Steve Scala of TD Cowen maintained a Buy rating on AstraZeneca, with a price target of $240.00.

Steve Scala has given his Buy rating due to a combination of factors, including AstraZeneca’s broad exposure to large, fast‑growing therapy areas and a series of near‑term events that will allow investors to track execution. He expects the company’s earnings to expand faster than the sector, while its valuation still looks attractive when considering both total return potential and price‑to‑earnings metrics.

He also highlights a powerful portfolio led by Tagrisso, Enhertu, Imfinzi, Ultomiris, and Calquence, which provides a durable foundation for new launches and pipeline assets with substantial long‑term sales prospects. In his view, investor worries about industry pricing, clinical readout risk, and long‑term patent and margin pressures are manageable given AstraZeneca’s diversified pipeline, innovation track record, and credible path toward its revenue and profitability goals.

In another report released on March 16, Berenberg Bank also assigned a Buy rating to the stock with a £170.00 price target.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.